Dario Cattaneo

List of Publications by Year in Descending Order

157 papers	4,080 citations	30 h-index	60 g-index
159 ext. papers	4,624 ext. citations	5.1 avg, IF	5.31 L-index

#	Paper	IF	Citations
157	Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios.. *Expert Review of Anti-Infective Therapy*, **2022**, 1-8	5.5	0
156	Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report.. *International Journal of STD and AIDS*, **2022**, 9564624221096299	1.4	
155	Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience. *World Journal of Biological Psychiatry*, **2021**, 22, 34-45	3.8	3
154	Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. *Aids*, **2021**, 35, 2551-2553	3.5	0
153	Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients. *British Journal of Clinical Pharmacology*, **2021**,	3.8	1
152	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 64-68	6.1	11
151	Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP. *Aids*, **2021**, 35, 522-524	3.5	
150	Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. *Drugs and Aging*, **2021**, 38, 341-346	4.7	2
149	Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". *Clinical Pharmacokinetics*, **2021**, 60, 829-831	6.2	1
148	ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. *Pharmacogenomics Journal*, **2021**, 21, 586-593	3.5	2
147	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. *Clinical Pharmacokinetics*, **2021**, 60, 103-109	6.2	6
146	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. *Journal of Medical Virology*, **2021**, 93, 1421-1427	19.7	17
145	Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts. *European Journal of Clinical Pharmacology*, **2021**, 77, 791-792	2.8	1
144	Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients: A Call for Action?. *Clinical Pharmacokinetics*, **2021**, 60, 603-609	6.2	1
143	In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5. *Biomedicine and Pharmacotherapy*, **2021**, 139, 111631	7.5	1
142	Fosfomycin therapeutic drug monitoring in real-life: development and validation of a LC-MS/MS method on plasma samples. *Journal of Chemotherapy*, **2021**, 1-10	2.3	
141	Does lopinavir really inhibit SARS-CoV-2?. *Pharmacological Research*, **2020**, 158, 104898	10.2	26

140	Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2704-2706	5.1	26
139	Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. *Clinical Infectious Diseases*, **2020**, 71, 2276-2278	11.6	114
138	Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings. *Drugs in R and D*, **2020**, 20, 155-160	3.4	1
137	Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1354-1356	5.1	1
136	Darunavir does not prevent SARS-CoV-2 infection in HIV patients. *Pharmacological Research*, **2020**, 157, 104826	10.2	40
135	Use of Direct Oral Anticoagulants in People Living with HIV: A Single-Center Experience. *Seminars in Thrombosis and Hemostasis*, **2020**, 46, 999-1001	5.3	1
134	Case of Suboptimal Linezolid Exposure: Is There a Role for Pharmacogenetics?. *Therapeutic Drug Monitoring*, **2020**, 42, 347-348	3.2	1
133	Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review. *Therapeutic Drug Monitoring*, **2020**, 42, 64-74	3.2	6
132	Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. *Therapeutic Drug Monitoring*, **2020**, 42, 83-92	3.2	21
131	Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation. *Therapeutic Drug Monitoring*, **2020**, 42, 330-334	3.2	3
130	Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. *Drugs and Aging*, **2020**, 37, 925-933	4.7	12
129	Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report. *International Journal of STD and AIDS*, **2020**, 31, 1008-1010	1.4	3
128	Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2020**, 84, e17-e20	3.1	1
127	Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. *Blood Advances*, **2020**, 4, 3648-3658	7.8	13
126	Association of HIV Infection with Epilepsy and Other Comorbid Conditions. *AIDS and Behavior*, **2020** , 24, 1051-1055	4.3	0
125	Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. *World Journal of Biological Psychiatry*, **2020**, 21, 651-657	3.8	6
124	The management of anti-infective agents in intensive care units: the potential role of a FastQ pharmacology. *Expert Review of Clinical Pharmacology*, **2020**, 13, 355-366	3.8	2
123	Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure. *Frontiers in Pediatrics*, **2019**, 7, 309	3.4	10

122	Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic. *AIDS Reviews*, **2019**, 21, 40-49	1.5	8
121	Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. *Expert Opinion on Drug Metabolism and Toxicology*, **2019**, 15, 245-252	5.5	8
120	R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor- in primary CNS lymphoma. *Blood*, **2019**, 134, 252-262	2.2	29
119	Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report. *European Journal of Clinical Pharmacology*, **2019**, 75, 1177-1178	2.8	2
118	Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis. *Clinical Pharmacokinetics*, **2019**, 58, 1345-1350	6.2	1
117	Different effects of glucocorticoids on darunavir plasma concentrations. *European Journal of Clinical Pharmacology*, **2019**, 75, 733-735	2.8	2
116	No effects of Hypericum-containing complex on dolutegravir plasma trough concentrations: a case report. *European Journal of Clinical Pharmacology*, **2019**, 75, 1467-1468	2.8	2
115	Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV. *Expert Opinion on Drug Metabolism and Toxicology*, **2019**, 15, 927-935	5.5	10
114	Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. *European Journal of Drug Metabolism and Pharmacokinetics*, **2019**, 44, 319-327	2.7	19
113	Selective serotonin reuptake inhibitorsQpassage into human milk of lactating women. *Journal of Maternal-Fetal and Neonatal Medicine*, **2019**, 32, 3020-3025	2	2
112	Dolutegravir and metformin: a clinically relevant or just a pharmacokinetic interaction?. *Aids*, **2018**, 32, 532-533	3.5	7
111	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2018**, 77, 86-92	3.1	19
110	How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life?. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2271-2273	5.1	5
109	Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?. *Obesity*, **2018**, 26, 1251-1252	3	5
108	The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration. *Antiviral Therapy*, **2018**, 23, 467-469	1.6	2
107	Comparison of the ARK Immunoassay With High-Performance Liquid Chromatography With Ultraviolet Detection for Therapeutic Drug Monitoring of Linezolid. *Therapeutic Drug Monitoring*, **2018**, 40, 140-143	3.2	6
106	Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?. *Pharmacopsychiatry*, **2018**, 51, 270-271	2	7
105	Intraindividual and Interindividual Variability of Olanzapine Trough Concentrations in Patients Treated With the Long-Acting Injectable Formulation. *Journal of Clinical Psychopharmacology*, **2018**, 38, 365-369	1.7	6

104	Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2018**, 78, 193-201	3.1	15
103	Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. *European Journal of Drug Metabolism and Pharmacokinetics*, **2017**, 42, 559-572	2.7	3
102	Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational Study. *Therapeutic Drug Monitoring*, **2017**, 39, 197-201	3.2	13
101	Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction. *Aids*, **2017**, 31, 867-868	3.5	10
100	How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2017**, 75, e24-e26	3.1	15
99	Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disorder: A Prospective Observational Study. *Therapeutic Drug Monitoring*, **2017**, 39, 441-445	3.2	5
98	Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 1842-1844	5.1	16
97	Is it time to revise linezolid dose in elderly patients?. *European Journal of Clinical Pharmacology*, **2017**, 73, 1335-1336	2.8	5
96	Dosing Colistin Properly: Let's Save "Our Last Resort Old Drug!". *Clinical Infectious Diseases*, **2017**, 65, 870	11.6	9
95	Application of Quality by Design Approach to Bioanalysis: Development of a Method for Elvitegravir Quantification in Human Plasma. *Therapeutic Drug Monitoring*, **2017**, 39, 531-542	3.2	3
94	Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 1183-1192	5.5	5
93	Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?. *Antiviral Therapy*, **2017**, 22, 353-356	1.6	10
92	Second generation antipsychotics in "real-life" paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. *Expert Opinion on Drug Safety*, **2016**, 15, 1-8	4.1	16
91	Therapeutic drug management of linezolid: a missed opportunity for clinicians?. *International Journal of Antimicrobial Agents*, **2016**, 48, 728-731	14.3	25
90	Determinants of bone diseases in tenofovir-treated HIV patients. *Aids*, **2016**, 30, 1686-7	3.5	1
89	Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients. *Journal of Pharmaceutical Analysis*, **2016**, 6, 396-403	14	26
88	Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. *European Journal of Clinical Pharmacology*, **2016**, 72, 285-93	2.8	18
87	Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1341-5	5.1	4

86	Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 533-44	5.5	39
85	Orlistat: weight lost at cost of HIV rebound. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1739-41	5.1	7
84	Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. *Bioanalysis*, **2016**, 8, 275-83	2.1	26
83	Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. *European Journal of Clinical Pharmacology*, **2016**, 72, 365-7	2.8	3
82	Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. *Therapeutic Drug Monitoring*, **2016**, 38, 285-7	3.2	1
81	Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma. *Therapeutic Drug Monitoring*, **2016**, 38, 407-13	3.2	16
80	Identification of Different Patterns of Dabigatran In Vivo Bioactivation in Patients on Maintenance Anticoagulation Therapy. *Therapeutic Drug Monitoring*, **2016**, 38, 814-816	3.2	
79	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. *European Respiratory Journal*, **2016**, 47, 1287-8	13.6	3
78	When food can make the difference: The case of elvitegravir-based co-formulation. *International Journal of Pharmaceutics*, **2016**, 512, 301-304	6.5	7
77	Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study. *Therapeutic Drug Monitoring*, **2015**, 37, 119-25	3.2	2
76	Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring. *European Journal of Clinical Pharmacology*, **2015**, 71, 383-5	2.8	3
75	Prolonged inductive effect of rifampicin on linezolid exposure. *European Journal of Clinical Pharmacology*, **2015**, 71, 643-4	2.8	8
74	Effect of hepatitis B and C clearance on atazanavir exposure. *European Journal of Clinical Pharmacology*, **2015**, 71, 1409-11	2.8	0
73	Long-term renal effects of tenofovir-disoproxil-fumarate in vertically HIV-infected children, adolescents, and young adults: a 132-month follow-up study. *Clinical Drug Investigation*, **2015**, 35, 419-26	3.2	8
72	Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2918-20	5.1	10
71	Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. *International Journal of Antimicrobial Agents*, **2015**, 45, 545-9	14.3	4
70	Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 435-44	5.9	33
69	Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?. *PLoS ONE*, **2015**, 10, e0123670	3.7	22

68	Serotonin reuptake inhibitors in pregnancy: can genes help us in predicting neonatal adverse outcome?. *BioMed Research International*, **2014**, 2014, 276918	3	6
67	Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers. *Drug Design, Development and Therapy*, **2014**, 8, 411-9	4.4	5
66	Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients. *ClinicoEconomics and Outcomes Research*, **2014**, 6, 341-8	1.7	5
65	Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint. *Aids*, **2014**, 28, 2477-80	3.5	10
64	Lights and shadows of the actual European guidelines on bioanalytical method validation: the case of raltegravir. *Therapeutic Drug Monitoring*, **2014**, 36, 739-45	3.2	6
63	Are non-serious adverse reactions to psychiatric drugs really non-serious?. *Journal of Child and Adolescent Psychopharmacology*, **2013**, 23, 394-400	2.9	8
62	Pharmacovigilance knowledge in family paediatricians. A survey study in Italy. *Health Policy*, **2013**, 113, 216-20	3.2	10
61	Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. *International Journal of Antimicrobial Agents*, **2013**, 41, 586-9	14.3	75
60	Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients. *Fundamental and Clinical Pharmacology*, **2013**, 27, 216-22	3.1	3
59	Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?. *Clinical Infectious Diseases*, **2013**, 57, 480-1	11.6	3
58	Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes. *Pediatric Infectious Disease Journal*, **2013**, 32, e403-5	3.4	14
57	Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. *PLoS ONE*, **2013**, 8, e80242	3.7	30
56	Optimizing immunosuppressive drug dosing in pediatric renal transplantation. Part of a special series on Paediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. *Pharmacological Research*, **2012**, 65, 163-7	10.2	10
55	Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients. *Journal of Clinical Pharmacology*, **2012**, 52, 440-5	2.9	12
54	Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient. *Fundamental and Clinical Pharmacology*, **2012**, 26, 204-6	3.1	2
53	Perceptions and patterns of use of generic drugs among Italian family pediatricians: first round results of a web survey. *Health Policy*, **2012**, 104, 247-52	3.2	32
52	Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. *Pharmacological Research*, **2012**, 65, 472-9	10.2	38
51	Acute kidney injury in a preterm infant homozygous for the C3435T polymorphism in the ABCB1 gene given oral morphine. *CKJ: Clinical Kidney Journal*, **2012**, 5, 431-3	4.5	1

50	Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 6132-6	5.9	27
49	Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 460-4	5.1	48
48	A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. *Pharmacological Research*, **2011**, 64, 210-7	10.2	35
47	Reply to Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients*QAids*, **2011**, 25, 1012-3; author reply 1011-2	3.5	2
46	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. *Transplantation Reviews*, **2011**, 25, 47-57	3.3	89
45	Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. *British Journal of Pharmacology*, **2010**, 160, 1550-60	8.6	32
44	Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 341-58	6.9	226
43	Clinical pharmacokinetics of ibuprofen arginine. *Current Clinical Pharmacology*, **2010**, 5, 239-45	2.5	9
42	Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen. *Transplantation*, **2010**, 89, 126-7	1.8	3
41	Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection. *Therapeutic Drug Monitoring*, **2010**, 32, 520-4	3.2	23
40	Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. *Therapeutic Drug Monitoring*, **2010**, 32, 782-6	3.2	34
39	Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen. *Journal of Clinical Pharmacology*, **2009**, 49, 773-81	2.9	7
38	Hepatitis C infection and chronic renal diseases. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 207-20	6.9	152
37	ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1404-15	12.7	56
36	Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects. *Pharmacological Research*, **2009**, 60, 221-8	10.2	24
35	Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. *Clinical Pharmacokinetics*, **2008**, 47, 827-38	6.2	66
34	Investigational drugs for diabetic nephropathy. *Expert Opinion on Investigational Drugs*, **2008**, 17, 1487-500	3.9	9
33	Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection. *Journal of Chromatographic Science*, **2008**, 46, 485-9	1.4	12

32	Development of a CE method for the determination of mycophenolic acid in human plasma: a comparison with HPLC. *Electrophoresis*, **2007**, 28, 3908-14	3.6	8
31	Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. *American Journal of Nephrology*, **2007**, 27, 630-8	4.6	11
30	C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. *Pharmacogenomics*, **2007**, 8, 1127-41	2.6	82
29	Regulatory T cells and T cell depletion: role of immunosuppressive drugs. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 1007-18	12.7	202
28	Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2007**, 2, 1147-53	6.9	47
27	Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. *Transplantation*, **2007**, 84, 956-64	1.8	84
26	Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. *Aids*, **2007**, 21, 2409-15	3.5	71
25	Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection. *Clinica Chimica Acta*, **2006**, 364, 354-8	6.2	29
24	Let assume that hepatitis C reduces the cardiovascular risk in dialysis patients: are there practical implications?. *Journal of Hepatology*, **2006**, 44, 837-8	13.4	3
23	Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. *Therapeutic Drug Monitoring*, **2006**, 28, 643-9	3.2	3
22	Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. *Clinical Biochemistry*, **2006**, 39, 1152-9	3.5	15
21	Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. *Journal of Renal Nutrition*, **2005**, 15, 71-6	3	12
20	Emerging drugs for diabetic nephropathy. *Expert Opinion on Emerging Drugs*, **2005**, 10, 747-71	3.7	8
19	Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation. *Clinica Chimica Acta*, **2005**, 355, 153-64	6.2	15
18	Cyclosporine formulation and Kaposi sarcoma after renal transplantation. *Transplantation*, **2005**, 80, 743-8	1.8	12
17	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 95-105		4
16	High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2005**, 816, 99-105	3.2	30
15	Generic cyclosporine formulations: more open questions than answers. *Transplant International*, **2005**, 18, 371-8	3	25

14	Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. *Expert Opinion on Therapeutic Patents*, **2004**, 14, 1553-1566	6.8	5
13	In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial. *Kidney International*, **2004**, 65, 1084-90	9.9	19
12	From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. *American Journal of Transplantation*, **2004**, 4, 299-310	8.7	49
11	Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. *American Journal of Transplantation*, **2004**, 4, 1345-51	8.7	53
10	Delayed graft function in kidney transplantation. *Lancet, The*, **2004**, 364, 1814-27	40	704
9	Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. *Personalized Medicine*, **2004**, 1, 53-62	2.2	1
8	Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. *Circulation*, **2003**, 107, 586-92	16.7	54
7	Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2002**, 774, 187-94	3.2	25
6	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. *Kidney International*, **2002**, 61, 1635-45	9.9	88
5	Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. *Kidney International*, **2002**, 62, 1060-7	9.9	181
4	How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 2898-908	12.7	131
3	Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. *Clinical Transplantation*, **2001**, 15, 402-9	3.8	66
2	Whole-Blood Calcineurin Activity Is Not Predicted by Cyclosporine Blood Concentration in Renal Transplant Recipients. *Clinical Chemistry*, **2001**, 47, 1679-1687	5.5	52
1	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-COV-2 infection: a retrospective cohort study		1